Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine as Synergistic Agent in Subarachnoid Block
NCT06662175Phase 3Not yet recruiting
- Start
- Nov 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of dexmedetomidine (2 arms). Primary endpoint: Duration of sensory and motor blockade. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
dexmedetomidine
Beyond the preview
Go deeper on NCT06662175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06662175.